Literature DB >> 7682425

Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.

A De Rossi1, C Zanotto, F Mammano, L Ometto, A Del Mistro, L Chieco-Bianchi.   

Abstract

The principal neutralizing domain (PND) of HIV-1, located within the third variable region (V3) of the gp120 envelope protein, is related to the humoral and cellular immune response. We studied the V3 PND-specific antibody response in 30 children with vertically acquired HIV-1 infection by determining the antibodies that bound synthetic peptides derived from the PND of the HIV-1MN, HIV-1SF-2, HIV-1SC, HIV-1IIIB, HIV-1RF, HIV-1ELI, and HIV-1Z6 virus strains. At a standard antigen concentration, we found that most sera (90%) reacted against PNDMN peptide, but 73.3% also cross-reacted against multiple PNDs. A search for high-affinity/avidity antibodies was conducted in an antigen-limited assay; at lower peptide concentrations, cross-reactivity was restricted to PNDMN and PNDSC in 12 of 22 broadly reactive sera. Sequence analysis of the V3 region of HIV-1 isolates indicated that patients with high-affinity/avidity antibodies to PNDMN and PNDSC had a PND with an internal 12-amino acid sequence (serotype-specific domain, SSD) that was highly homologous (> 90%) with the MN and SC SSD. Broadly reactive sera with low-affinity/avidity antibodies showed a lower degree of homology with the SSD sequence of all tested viral strains. The role of anti-PND antibodies in vertical transmission was further studied in 49 children born to HIV-1-seropositive mothers. No statistical correlation emerged between V3 antibodies and HIV-1 transmission, but we found that maternal V3 antibodies were lost soon after birth. This finding may be relevant to a new serological approach to the early diagnosis of vertically transmitted HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682425     DOI: 10.1089/aid.1993.9.221

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Binding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children.

Authors:  S S Prakash; Raiees Andrabi; Rajesh Kumar; S K Kabra; Rakesh Lodha; Madhu Vajpayee; Kalpana Luthra
Journal:  Viral Immunol       Date:  2011-12       Impact factor: 2.257

2.  Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease.

Authors:  F Salvatori; S Masiero; C Giaquinto; C M Wade; A J Brown; L Chieco-Bianchi; A De Rossi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

3.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.

Authors:  A J Conley; M K Gorny; J A Kessler; L J Boots; M Ossorio-Castro; S Koenig; D W Lineberger; E A Emini; C Williams; S Zolla-Pazner
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

Authors:  D Chargelegue; C M Stanley; C M O'Toole; B T Colvin; M W Steward
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

5.  Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activity.

Authors:  E Fenouillet; N Blanes; A Benjouad; J C Gluckman
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

6.  Relationship between the V3 loop and the phenotypes of human immunodeficiency virus type 1 (HIV-1) isolates from children perinatally infected with HIV-1.

Authors:  F Mammano; F Salvatori; L Ometto; M Panozzo; L Chieco-Bianchi; A De Rossi
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.